Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 12, 2025

XRP 2030 Price Prediction: Can XRP Reach $25 or Will $5 Be the Peak?

View original at finance.yahoo.com
XRP 2030 Price Prediction: Can XRP Reach $25 or Will $5 Be the Peak? Sundays Photography / Shutterstock.com Quick Read XRP traded between $1.75 and $3.65 over six months and now sits around $2.05…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Many banks use ODL for settlement, but still avoid holding XRP on their books due to price swings creating audit and compliance headaches

    80% confidence

  • In bearish case, XRP could trade between $3 and $5 by 2030 if institutional rollout loses momentum

    80% confidence

  • Ripple partners with six central banks on CBDC pilots including Georgia and Hong Kong

    80% confidence

  • In bullish case, XRP could reach $20-$25 range by 2030 with broad corridor coverage, active CBDC connections, and maturing privacy-powered settlement flows

    80% confidence

  • XRP traded between $1.75 and $3.65 over six months and now sits around $2.05

    80% confidence

  • XRP can reach $25 by 2030 if CBDC pilots mature, privacy features gain traction among enterprises, and stablecoins like RLUSD reach multi-billion-dollar scale

    80% confidence

  • A $25 XRP by 2030 requires $1.4T market cap and trillions in annual settlement volume through XRPL

    80% confidence

  • In base case, XRP could trade between $8 and $12 by 2030 with steady but not dramatic adoption

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
XRP 2030 Price Prediction: Can XRP Reach $25 or Will $5 Be the Peak? — Source | Via News | ViaNews Market